Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items grows, but more slowly than its trailing trend

Q1 FY2026 other non-cash items of $586K (cash outflow) rose 54.2% year over year, behind the +106.6% change in trailing-twelve-month other non-cash items. Sequentially, it fell 89.1% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.

Context

  • Other non-cash items amounted to 14966.1% of revenue in FY2025, up 11484.5 pp from a year earlier.
  • Other non-cash items increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +54.2% toward the trailing-twelve-month pace of +106.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$586K-89.1% QoQ
Last fiscal yearDec 2025
$8.83M+157.5% YoY
LTMMar 2026
$8.62M+106.6% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+54.2%——
1 year+157.5%——
3-year CAGR+6.9%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
8.83M USD
Year-over-year change
+157.5%
4-year CAGR
+82.6%

Other Non-Cash Items vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +106.6% is the 5th highest of 9, against a peer median of +123.8%.
  • Other non-cash items amounts to 14616.9% of revenue for AVTX, versus a peer median of 47.0%.
AVTX Competitors
Other Non-Cash Items for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$186.33M USD+554.3%+75.1%177.5%
ANABAnaptysBio, Inc.LTM Mar 2026$78.61M USD+42.2%-12.8%33.8%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$33.58M USD-41.1%—37.1%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$8.62M USD+106.6%+6.9%14616.9%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$7.1M USD-83.8%——
IFRXInflaRx N.V.LTM Mar 2026€6.04M EUR+205.4%—20599.5%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$4.76M USD-94.7%-21.2%56.9%
QTTBQ32 Bio Inc.LTM Mar 2026$4.74M USD+1213.9%—8.8%
IMUXImmunic, Inc.LTM Mar 2026$595K USD+331.5%-76.4%—
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding AVTX) —+123.8%-17.0%47.0%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Depreciation & Amortization1.66M166K158K169K344K
Deferred Income Tax22K28K14K114K165K
Stock-Based Compensation8.17M7.55M3.48M5.85M13.62M
Change in Working Capital2.84M(60K)(9.24M)(4.71M)3.84M
Accounts Receivables1.12M2.88M1.78M(475K)0
Inventory(35K)18K20K00
Accounts Payables796K(487K)(2.44M)(163K)(146K)
Other Working Capital961K(2.47M)(8.61M)(4.07M)3.99M
Other Non-Cash Items794K7.22M6.46M(15.35M)8.83M
Operating Cash Flow(70.89M)(26.75M)(30.68M)(49.06M)(51.46M)
Capital Expenditures(113K)(95K)(158K)00
Acquisitions (Net)000356K0
Purchases of Investments0000(113.72M)
Sales of Investments000031.31M
Other Investing Activities0025K0690K
Investing Cash Flow(113K)(95K)(133K)356K(81.72M)
Debt Repayment32.9M(14.81M)(21.24M)00
Common Stock Issued71.93M107K46.22M115.63M15.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.93M067K60.22M(510K)
Financing Cash Flow106.76M(14.7M)25.04M175.85M14.59M
Effect of Forex Changes096K000
Net Change in Cash35.76M(41.45M)(5.77M)127.15M(118.59M)
Free Cash Flow(71.01M)(26.85M)(30.84M)(49.06M)(51.46M)

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.